Tesamorelin is a synthetic growth hormone-releasing peptide (GHRP) designed to stimulate the body’s natural production of growth hormone (GH) from the pituitary gland.It is primarily indicated for treating HIV-associated lipodystrophy—a condition causing abnormal fat accumulation, often around the abdomen, in people living with HIV.

By binding to specific receptors in the pituitary, Tesamorelin triggers a controlled release of GH, which in turn activates insulin-like growth factor 1 (IGF-1). Clinical studies show it effectively reduces excess abdominal visceral fat, a key concern linked to increased metabolic and cardiovascular risks in patients with HIV lipodystrophy. Beyond fat management, it may also support modest improvements in lipid profiles and insulin sensitivity.

Administered via subcutaneous injection, Tesamorelin is typically used under medical supervision. Common mild side effects include injection-site reactions (redness, soreness) or mild flu-like symptoms. It is not intended for anti-aging or performance-enhancing purposes. For patients seeking targeted relief from HIV-related fat accumulation, Tesamorelin offers a science-backed, FDA-approved solution aligned with clinical best practices.

Product Usage: This PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website is for educational purposes only. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabled as a drug, food or cosmetic.